Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 399

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 399
---
 NLS has been supplied by NLS and all information contained in this document relating to Kadimastem has been supplied by Kadimastem. Information provided by one entity does not constitute any representation, estimate or projection of the other entity. If you would like additional copies of this document or if you have questions about the Merger, you should contact via phone or in writing: NLS Pharmaceutics Ltd.
The Circle 6
8058 Zurich, Switzerland
Tel: +41.44.512.2150
Attn: Alexander Zwyer, acz@nls -pharma.com If you are a shareholder of NLS and would like to request documents, please do so by, 2025 to receive them before the NLS Extraordinary Shareholders’ Meeting. If you request any documents from NLS, NLS will mail them to you by first class mail, or another equally prompt means. Neither NLS, nor Kadimastem has authorized anyone to give any information or make any representation about the Merger or their companies that is different from, or in addition to, that contained in this proxy statement/prospectus or in any of the materials that have been incorporated in this proxy statement/prospectus. Therefore, if anyone does give you information of this sort, you should not rely on it. If you are in a jurisdiction where offers to exchange or sell, or solicitations of offers to exchange or purchase, the securities offered by this proxy statement/prospectus or the solicitation of proxies is unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this proxy statement/prospectus does not extend to you. The information contained in this proxy statement/prospectus speaks only as of the date of this proxy statement/prospectus unless the information specifically indicates that another date applies. 241 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE The SEC allows NLS to “incorporate by reference” information into this proxy statement/prospectus, which means that we can disclose important information to you by referring you to other documents which we have filed or will file with the SEC. We are incorporating by reference in this proxy statement/prospectus the documents listed below and all amendments or supplements we may file to such documents, as well as any future filings we may make with the SEC on Form 20 -Funder the Exchange Act before the time that all of the securities offered by this proxy statement/prospectus have been sold